INOVIO Doses First Participant in Phase 2 Trial for its DNA Vaccine Against Middle East Respiratory Syndrome (MERS), a Coronavirus Disease

A biotechnology company has announced the start of Phase 2 trial in the development of the first vaccine against MERS.

Article from PR Newswire